Clinical Trial Update: Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination

View source ↗

Summary

Ipsen announces a completed clinical trial evaluating cabozantinib in advanced renal cell carcinoma after first-line immuno-oncology checkpoint inhibitor-contai…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Ipsen | Conditions: Advanced Renal Cell Carcinoma (aRCC) | Status: COMPLETED